Slide 1: Lasa Supergenerics Limited – Regulation 30 filing letter
LASA SUPERGENERICS LIMITED Corporate Office : B/207, “CITI POINT”, Near Kohinoor Hotel, J.B. Nagar, Andheri (E), Mumbai -59 Tel : +91 22 4970 1092 » Email : info@lasalabs.com » Website : www.lasalabs.com LASA SUPERGENERICS LIMITED Ref. No.: LASA/SE/18-19/024 Tuesday May 29, 2018 To, To, Corporate Se
Slide 2: Q4 & FY18 Earnings Presentation
Lasa Supergenerics Limited Q4 & FY18 Earnings Presentation May 2018
Slide 3: Safe harbor
Safe harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Lasa Supergenerics Limited (the “Company”) solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall
Slide 4: Table of Contents
Table of Contents 01 Chairman’s Message 02 Consolidated Financial Highlights 03 Company Overview 04 Business Overview 05 Growth Strategies
Slide 5: Chairman's Message
Chairman’s Message
Slide 6: Chairman's Message
Chairman’s Message Commenting on the results, Dr. Omkar Herlerkar, ,Chairman & Managing Director, Lasa Supergenerics Ltd. said : "This full financial year end 2017-18, we have registered a net revenue growth of over 23% and exceptional increase in our overall profit by over 400%. This growth has bee
Slide 7: Consolidated Financial Highlights
Consolidated Financial Highlights
Slide 8: Quarterly Profitability Highlights – Q4 FY18
Quarterly Profitability Highlights – Q4 FY18 Rs crore Q4 FY18 Q3 FY18 Q2 FY18 Q1 FY18 Revenue from Operations 59.31 60.99 64.53 61.01 Excise 0.00 0.00 0.00 2.31 Net Revenue 59.31 60.99 64.53 58.70 Raw Material & Fuel costs 51.22 40.66 42.71 36.91 Employee Cost 2.73 2.60 2.57 2.37 Other costs 5.93 4.
Slide 9: Recent Developments
Recent Developments • Received WHO-GMP Certificate for Mahad Unit Received WHO-GMP Certificate for Mahad Unit, post inspection by the regulatory officials/Commissioner of food and drug administration on 6th July 2017, 7th July 2017, 11thJanuary 2018 and 22nd March 2018 WHO GMP certificate will rem
Slide 10: Annual Profitability Highlights – FY18
Annual Profitability Highlights – FY18 23% 422% Net Revenue Rs. 244 Cr PAT Rs. 12 Cr. 388 bps 370% PAT Margin 5.07 % EPS Rs. 5.40 v/s Rs. 1.15 9
Slide 11: Yearly Profitability Highlights – FY18
Yearly Profitability Highlights – FY18 Rs crore FY18 FY17 Y-o-Y% Revenue from Operations 245.84 218.23 13% Excise 2.31 19.48 • Net Revenue stood at Rs. Net Revenue 243.53 198.75 23% 244 crore registered a Raw Material & Fuel costs 171.51 130.89 growth of 23% on YoY basis Employee Cost 10.27 9.55 Oth
Slide 12: Balance Sheet Highlights
Balance Sheet Highlights As on 31st As on 31st As on 31st As on 31st Rs crore Mar 2018 Mar 2017 Rs crore Mar 2018 Mar 2017 Shareholder’s Funds 117.34 75.49 Non-current assets 177.60 148.84 Prop., Plant & Equip. 163.65 112.86 Share Capital 22.86 0.05 CWIP 6.99 29.34 Other Equity 94.48 75.44 Intangibl
Slide 13: Company Overview
Company Overview
Slide 14: Company Overview
Company Overview Leader in Vet APIs Market Market Share Acquired in 2012 with annual About 35% market share in turnover of Rs 1 crore. Currently, 01 stands at Rs ~200 crore Indian animal healthcare industry 08 02 Leader in Catalyst Chemistry Established as a leader in Strong Pipeline of ‘catalyst’ c
Slide 15: Management Team
Management Team Dr. Omkar Herlekar Sumant Kharasambale 04 Ajay Sukhwani 02 Independent Director 06 Chairman & Managing Whole Time Director Director Shivanand Hegde Ekta Gurnasinghani Bachelors of Commerce Hardesh Tolani Handles plant operation, degree from University of Multiple graduation degrees M
Slide 16: Business Overview
Business Overview
Slide 17: Classification of Anthelmintics
Classification of Anthelmintics Piperazines Benzimidazole Imidazo Thiazole Heterocyclics Anthelmintics Amide Nitro Derivative Vinyl Pyrimidines 16
Slide 18: Why Deworming in Cattle / Importance of Deworming in Cattle
Why Deworming in Cattle / Importance of Deworming in Cattle Farm grazing animals such as cow, goat, Possibility of sheep etc. to graze closer to the faecal infection material found in grass Cattle get infected with parasites such as Consequence roundworms, tapeworms and liver fluke Ill effect on the
Slide 19: Strong Product Portfolio
Strong Product Portfolio 01 03 05 07 02 04 06 Albendazole Fenbendazole Nitroxynil Oxfendazole Toldimphos Sodium Providon Iodine Halquinol • Leader in Veterinary API products, Animal feed ingredients, Reagents for therapeutic Use & other API products • No Product Dependency - Top seven products contr
Slide 20: Industry Entry Barriers
Industry Entry Barriers… Backward Integration • Our fully backward integrated API manufacturing model helps us to lower our product cost Catalyst Backed Products • Extensive use of catalysts in API manufacturing helps us to increase our gross profit margins Catalyst Process Patents • Seven catalyst
Slide 21: Process Entry Barriers
Process Entry Barriers… Pressure reactions up to 50 atmospheres High temperature Vacuum handling azetrope separation up to 1-torr Cryogenic Multi-stage reactions fractional up to —75 °c distillation Temperature Column handling chromatography up to 400 °c Membrane filtration & Reverse osmosis Flash &
Slide 22: Competitive Advantages of Backward Integration / Edge Over Others
Competitive Advantages of Backward Integration / Edge Over Others Niche In Backward Integration Basic Petrochemical Basic Intermediate Derivatives [N-1] API Basic Organic Advanced Intermediate Molecule Efficient handling of toxic gases and moisture sensitive compounds 21
Slide 23: Advantages of Catalyst Chemistry
Advantages of Catalyst Chemistry Reduces Time • Plays crucial role in lowering labour costs Generates Less Emission • Cuts down on time cycle • Significantly less by-products • Increases productivity in and effluent discharge same infrastructure, • Curtails toxic threshold Leadings to handsome Ebitd
Slide 24: Our Journey So Far
Our Journey So Far…. Lasa was acquired in April’12 as a 100% subsidiary by Omkar speciality chemicals limited (OSCL) 23
Slide 25: Manufacturing Facilities
Manufacturing Facilities Location Chiplun Unit Maharashtra Mahad Unit Maharashtra Unit V, Chiplun Maharashtra Unit VI, Chiplun Maharashtra Total Capacity – 4,300 Tonnes Per Annum 24
Slide 26: Product-wise Global Reach
Product-wise Global Reach *Country Albendazole Fenbendazole Oxfendazole Closantel Cyromazine Halquinol Nitroxline PV-I Ricobendazole Toldimphos Oxycloza Australia Bangladesh Brazil Canada China Colombia Egypt Europe Germany Hungary Jordan Kenya *Above are various countries consuming relevant product
Slide 27: Product-wise Global Reach
Product-wise Global Reach *Country Albendazole Fenbendazole Oxfendazole Closantel Cyromazine Halquinol Nitroxline PV-I Ricobendazole Toldimphos Oxycloza Korea Malaysia Brazil Merchant exporters Pakistan Peru Russia Saudi arabia South africa South america Usa West indies *Above are various countries
Slide 28: Certifications / Regulatory Approvals
Certifications / Regulatory Approvals 01 D M Fs & F DA 10 approved products 4 approved pharma zones 02 Pa te nt s 7 Process patents filed 03 Sanctions Certified WHO and C-GMP units 27
Slide 29: Process Patents Filed
7 Process Patents Filed Method for the simplified production of Method for the preparation of salicylanilide Process for the preparation of benzimidazole An improved process for the preparation fasciolicide and derivative antiparasitic derivative derivative as anthelmintic agents of triazine derivat
Slide 30: Quality and Assurance
Quality and Assurance • Rm/pm analysis • EU and US GMP training • Finished products analysis • Sop compliance • Finished products analysis • Audit of facility for compliance • In-process checks • In-process counter checks, • Stability studies critical sampling • Instrumental analysis & finished prod
Slide 31: Growth Strategies
Growth Strategies
Slide 32: Growth Strategies
Growth Strategies Expansion & Entry in newer New Product Development geographies • In house catalyst chemistry • Commissioning of a multipurpose expertise enables us to plant with capability to handle introduce new products various high pressure unit • Fully backward integration operations enables u
Slide 33: Thank You
Thank You 540702 LASA LASA:IN LASA.NS For further information, please contact: Company : Investor Relations Advisors : Lasa Supergenerics Ltd. Bridge Investor Relations Pvt. Ltd. CIN: L24233MH2016PLC274202 CIN: U74900MH2016PTC273679 Dr. Omkar Herlekar Ms. Savli Mangle Chairman & MD savli@bridge-ir.c